In Q2 2026, PTC Therapeutics recognized significant milestone payments tied to regulatory approvals for its rare disease portfolio, notably Sephience, reflecting the company’s success in expanding patient access and product commercialization. This milestone-driven revenue recognition introduces timing variability but affirms the value of recent pipeline expansions stemming from strategic acquisitions like Censa. PTC’s management continues to navigate complex Medicaid Drug Rebate Program adjustments that materially impact net sales and revenue recognition. The company’s liquidity remains robust with over $2 billion in combined cash and investments, though near-term refinancing of $93 million in convertible senior notes due September 2026 demands attention. Peers such as BioMarin similarly balance milestone-dependent revenues with ongoing clinical development, positioning PTC competitively within the niche rare disease biotech landscape.